New research highlights the promising combination of tarlatamab and checkpoint inhibitors, showing improved survival rates in extensive-stage small cell lung cancer patients.
Kelly Paulson, MD, PhD
Kelly Paulson, MD, is a medical oncologist at Swedish Cancer Institute Medical Oncology in Edmonds, WA.
Articles by Kelly Paulson, MD, PhD
New findings reveal tarlatamab combined with anti–PD-L1 agents significantly improves survival in extensive-stage small cell lung cancer, prompting further research.
Dr Kelly Paulson shares groundbreaking insights from the DeLLphi-303 study, highlighting new immunotherapy strategies for small cell lung cancer treatment.
Kelly Paulson, MD, PhD, a fellow at Seattle Cancer Care Alliance, discusses single-cell RNA sequencing in merkel cell carcinoma during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
Latest Updated Articles
Future Directions With Tarlatamab in Small Cell Lung CancerPublished: September 22nd 2025 | Updated:
Single-Cell RNA Sequencing in Merkel Cell CarcinomaPublished: November 14th 2017 | Updated:
- DeLLphi-303 Study: Tarlatamab's Impact on Small Cell Lung Cancer
Published: September 19th 2025 | Updated: